Literature DB >> 22665544

Systemic retinoid therapy for chemoprevention of nonmelanoma skin cancer in a patient treated with vemurafenib.

Rachael Anforth1, Tatiana Cristina Moraes Pinto Blumetti, Azura Mohd Affandi, Pablo Fernandez-Penas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22665544     DOI： 10.1200/JCO.2011.39.8594

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  8 in total

Review 1.  Management of the cutaneous adverse effects of antimelanoma therapy.

Authors:  Rose Congwei Liu; Germana Consuegra; Pablo Fernández-Peñas
Journal:  Melanoma Manag       Date:  2017-11-22

Review 2.  Managing the skin toxicities from new melanoma drugs.

Authors:  John C Mavropoulos; Timothy S Wang
Journal:  Curr Treat Options Oncol       Date:  2014-06

Review 3.  BRAF inhibitors: experience in thyroid cancer and general review of toxicity.

Authors:  M E Cabanillas; A Patel; B P Danysh; R Dadu; S Kopetz; G Falchook
Journal:  Horm Cancer       Date:  2014-12-03       Impact factor: 3.869

4.  Analysis of dermatologic events in vemurafenib-treated patients with melanoma.

Authors:  Mario E Lacouture; Madeleine Duvic; Axel Hauschild; Victor G Prieto; Caroline Robert; Dirk Schadendorf; Caroline C Kim; Christopher J McCormack; Patricia L Myskowski; Olivia Spleiss; Kerstin Trunzer; Fei Su; Betty Nelson; Keith B Nolop; Joseph F Grippo; Richard J Lee; Matthew J Klimek; James L Troy; Andrew K Joe
Journal:  Oncologist       Date:  2013-03-01

Review 5.  Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma.

Authors:  Geoffrey T Gibney; Jane L Messina; Inna V Fedorenko; Vernon K Sondak; Keiran S M Smalley
Journal:  Nat Rev Clin Oncol       Date:  2013-05-28       Impact factor: 66.675

6.  Melanoma patients under vemurafenib: prospective follow-up of melanocytic lesions by digital dermoscopy.

Authors:  Marie Perier-Muzet; Luc Thomas; Nicolas Poulalhon; Sébastien Debarbieux; Pierre-Paul Bringuier; Gerard Duru; Lauriane Depaepe; Brigitte Balme; Stephane Dalle
Journal:  J Invest Dermatol       Date:  2013-11-07       Impact factor: 8.551

7.  Adverse Effects of Vemurafenib on Skin Integrity: Hyperkeratosis and Skin Cancer Initiation Due to Altered MEK/ERK-Signaling and MMP Activity.

Authors:  Marius Tham; Hans-Jürgen Stark; Anna Jauch; Catherine Harwood; Elizabeth Pavez Lorie; Petra Boukamp
Journal:  Front Oncol       Date:  2022-01-31       Impact factor: 6.244

8.  RASopathic skin eruptions during vemurafenib therapy.

Authors:  Jeannine D Rinderknecht; Simone M Goldinger; Sima Rozati; Jivko Kamarashev; Katrin Kerl; Lars E French; Reinhard Dummer; Benedetta Belloni
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.